Log in to save to my catalogue

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or ref...

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or ref...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2561489424

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

About this item

Full title

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Publisher

London: Elsevier Ltd

Journal title

The Lancet (British edition), 2021-08, Vol.398 (10301), p.665-674

Language

English

Formats

Publication information

Publisher

London: Elsevier Ltd

More information

Scope and Contents

Contents

There is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target. Teclistamab is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple myeloma cells. The aim of the MajesTEC-1 study was to evaluate the safety, tolerability, and preliminary efficacy of...

Alternative Titles

Full title

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2561489424

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2561489424

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(21)01338-6

How to access this item